The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer
The soluble urokinase-type plasminogen activator receptor (suPAR) is prognostic for overall survival (OS) in colorectal cancer (CRC). Our study explored the association between baseline suPAR and OS and progression-free survival (PFS) in metastatic CRC (mCRC). It is also the first study to explore t...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/20/5100 |
| _version_ | 1797515082967547904 |
|---|---|
| author | Kristian Blomberg Torben F. Hansen Claus L. Brasen Jeppe B. Madsen Lars H. Jensen Caroline B. Thomsen |
| author_facet | Kristian Blomberg Torben F. Hansen Claus L. Brasen Jeppe B. Madsen Lars H. Jensen Caroline B. Thomsen |
| author_sort | Kristian Blomberg |
| collection | DOAJ |
| description | The soluble urokinase-type plasminogen activator receptor (suPAR) is prognostic for overall survival (OS) in colorectal cancer (CRC). Our study explored the association between baseline suPAR and OS and progression-free survival (PFS) in metastatic CRC (mCRC). It is also the first study to explore the association between the initial change in suPAR level and OS, PFS and the first CT response evaluation. The study included 132 patients with mCRC treated with chemotherapy (FOLFIRI) with or without an EGFR-inhibitor. Blood samples were drawn before the first treatment cycle and in between the first and second treatment cycle. suPAR levels were determined using an ELISA assay. Using the Kaplan-Meyer method, we demonstrated a significantly shorter OS for patients with suPAR levels above the median (HR = 1.79, 95%CI = 1.10–2.92, <i>p</i> = 0.01). We also showed association between plasma suPAR level, gender and performance status (PS). However, we could not show any association with PFS, and analysis on the change in suPAR level provided no significant results. The results showing association between baseline suPAR and OS are in line with previous findings. |
| first_indexed | 2024-03-10T06:40:35Z |
| format | Article |
| id | doaj.art-8d27f079cb97410d8546027cc3781c8c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T06:40:35Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-8d27f079cb97410d8546027cc3781c8c2023-11-22T17:40:15ZengMDPI AGCancers2072-66942021-10-011320510010.3390/cancers13205100The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal CancerKristian Blomberg0Torben F. Hansen1Claus L. Brasen2Jeppe B. Madsen3Lars H. Jensen4Caroline B. Thomsen5Department of Health Science, University of Southern Denmark, 5000 Odense, DenmarkDanish Colorectal Cancer Center South, Department of Oncology, University Hospital of Southern Denmark, 7100 Vejle, DenmarkDepartment of Regional Health Research, University of Southern Denmark, 5000 Odense, DenmarkDepartment of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern Denmark, 7100 Vejle, DenmarkDanish Colorectal Cancer Center South, Department of Oncology, University Hospital of Southern Denmark, 7100 Vejle, DenmarkDanish Colorectal Cancer Center South, Department of Oncology, University Hospital of Southern Denmark, 7100 Vejle, DenmarkThe soluble urokinase-type plasminogen activator receptor (suPAR) is prognostic for overall survival (OS) in colorectal cancer (CRC). Our study explored the association between baseline suPAR and OS and progression-free survival (PFS) in metastatic CRC (mCRC). It is also the first study to explore the association between the initial change in suPAR level and OS, PFS and the first CT response evaluation. The study included 132 patients with mCRC treated with chemotherapy (FOLFIRI) with or without an EGFR-inhibitor. Blood samples were drawn before the first treatment cycle and in between the first and second treatment cycle. suPAR levels were determined using an ELISA assay. Using the Kaplan-Meyer method, we demonstrated a significantly shorter OS for patients with suPAR levels above the median (HR = 1.79, 95%CI = 1.10–2.92, <i>p</i> = 0.01). We also showed association between plasma suPAR level, gender and performance status (PS). However, we could not show any association with PFS, and analysis on the change in suPAR level provided no significant results. The results showing association between baseline suPAR and OS are in line with previous findings.https://www.mdpi.com/2072-6694/13/20/5100suPARmetastatic colorectal cancermonitoring |
| spellingShingle | Kristian Blomberg Torben F. Hansen Claus L. Brasen Jeppe B. Madsen Lars H. Jensen Caroline B. Thomsen The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer Cancers suPAR metastatic colorectal cancer monitoring |
| title | The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer |
| title_full | The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer |
| title_fullStr | The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer |
| title_full_unstemmed | The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer |
| title_short | The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer |
| title_sort | soluble urokinase type plasminogen activator receptor as a biomarker for survival and early treatment effect in metastatic colorectal cancer |
| topic | suPAR metastatic colorectal cancer monitoring |
| url | https://www.mdpi.com/2072-6694/13/20/5100 |
| work_keys_str_mv | AT kristianblomberg thesolubleurokinasetypeplasminogenactivatorreceptorasabiomarkerforsurvivalandearlytreatmenteffectinmetastaticcolorectalcancer AT torbenfhansen thesolubleurokinasetypeplasminogenactivatorreceptorasabiomarkerforsurvivalandearlytreatmenteffectinmetastaticcolorectalcancer AT clauslbrasen thesolubleurokinasetypeplasminogenactivatorreceptorasabiomarkerforsurvivalandearlytreatmenteffectinmetastaticcolorectalcancer AT jeppebmadsen thesolubleurokinasetypeplasminogenactivatorreceptorasabiomarkerforsurvivalandearlytreatmenteffectinmetastaticcolorectalcancer AT larshjensen thesolubleurokinasetypeplasminogenactivatorreceptorasabiomarkerforsurvivalandearlytreatmenteffectinmetastaticcolorectalcancer AT carolinebthomsen thesolubleurokinasetypeplasminogenactivatorreceptorasabiomarkerforsurvivalandearlytreatmenteffectinmetastaticcolorectalcancer AT kristianblomberg solubleurokinasetypeplasminogenactivatorreceptorasabiomarkerforsurvivalandearlytreatmenteffectinmetastaticcolorectalcancer AT torbenfhansen solubleurokinasetypeplasminogenactivatorreceptorasabiomarkerforsurvivalandearlytreatmenteffectinmetastaticcolorectalcancer AT clauslbrasen solubleurokinasetypeplasminogenactivatorreceptorasabiomarkerforsurvivalandearlytreatmenteffectinmetastaticcolorectalcancer AT jeppebmadsen solubleurokinasetypeplasminogenactivatorreceptorasabiomarkerforsurvivalandearlytreatmenteffectinmetastaticcolorectalcancer AT larshjensen solubleurokinasetypeplasminogenactivatorreceptorasabiomarkerforsurvivalandearlytreatmenteffectinmetastaticcolorectalcancer AT carolinebthomsen solubleurokinasetypeplasminogenactivatorreceptorasabiomarkerforsurvivalandearlytreatmenteffectinmetastaticcolorectalcancer |